Loading…
← CockpitCompetitor Analysis › ICUI ICU Medical, Inc.Open in the cockpit ↗

ICU Medical, Inc.ICUICompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of IV therapy systems, infusion pumps and consumables used in hospitals to safely deliver medications.

Momentum leader 85
Mkt cap
$4.46B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$50.6M
20-day average traded
Fwd P/E
19.4×
forward earnings
ROIC−WACC
-4.2 pp
WACC 8.7%
Hurdle
+7 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · USD$178.48
1D+0.9%
1W+0.1%
1M+10.8%
3M-2.2%
6M+38.0%
YTD+25.1%
1Y+32.7%
ATR %3.5%
Beta1.06
52w lowhigh7.5% off high

What ICU Medical does

Maker of IV therapy systems, infusion pumps and consumables used in hospitals to safely deliver medications.

Places infusion pumps in hospitals and then earns repeatedly from the disposable IV sets and connectors that must be used with them. Buying Pfizer's Hospira infusion business in 2017 made it much larger and added IV solutions, bags of saline and other fluids, a bulky, low-priced line.

Products and services

  • Infusion pumps (Plum, LifeCare)
  • IV sets/needle-free connectors
  • Critical care/vascular access consumables
  • Oncology closed-system transfer devices

Customers

  • Hospitals
  • Ambulatory infusion centers

Where it sits in the supply chain

  • Medical devices
  • IV therapy & infusion systems
  • Infusion pumps, IV sets & safety…

What could go right

  • Hospital infusion-pump replacement cycle
  • Oncology safety-device adoption

What could go wrong

  • Product recall/regulatory risk
  • Hospital capex cyclicality

Moat: narrow (switching costs, installed base, regulatory licence). Installed infusion-pump base and hospital contracts create high switching costs for a low-margin consumables business.

Headquarters: San Clemente, California · Founded: 1984 · Employees: 13,000

Named competitors

ICU Medical at a glance

Size ICU Medical (ICUI) is a United States Health Care company (Medical Specialties) with a market value of $4.46B, the 1263rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $178.48 on 18 Nov 2026.

Performance Over six months the shares gained 38.0%, against +26.1% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue fell 5.8% over the last twelve months (peer median +8.3%); the operating margin is 8.1% (peer median 13.6%).

Valuation It trades at 19.4× forward earnings against a peer median of 20.5× (8th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.2 points below its cost of capital (8.7% WACC).

Short interest Short interest is 6.7% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026ICUI 136Peer median 126
Six months, rebased to 100: ICU Medical against the median of its 20 peers (local-currency closes).

ICU Medical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.18B$2.23B$2.38B$2.26B$2.28B
Revenue growth—-6%+5%-1%—
Gross profit$746M$686M$822M$732M$663M
EBITDA$379M$325M$335M$290M$244M
Net income$60.3M$732,000-$118M-$29.7M-$74.3M
Free cash flow$209M$91.8M$125M$82.3M-$152M
Capital expenditure$77.7M$97.0M$90.2M$93.7M$99.3M
Total debt$1.21B$1.35B$1.64B$1.70B$1.74B

Quarterly statements and history in the cockpit →

ICU Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%GRALSHCSTVN002223MMEDDIA300677FIECDNAMMSI002432LIVNNVST1SXP603014TECNHAE4203AMBU-BAXGNICUI6-month return →1-month return →
Up and to the right = strong over both horizons. ICU Medical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%25×50×75×SHCSTVN002223MMEDDIA300677FIECDNAMMSI0024321SXPTECN4203AMBU-BAXGNICUIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ICU Medical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%SHCSTVN002223DIA300677FIE002432TECNHAEAMBU-BAXGNICUIGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. ICU Medical is the large dot.

ICU Medical competitors and peer comparison

Head to head with its named competitors (ICUI vs BDX vs BAX vs FRE.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
ICU Medical ICUI$4.46B+38%-6%8%19.4×18.9%
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%
Baxter International BAX$13.5B+39%+5%6%12.7×13.4%
Fresenius SE & Co. KGaA FRE.DE$32.7B+41%+7%10%14.7×7.0%
Terumo 4543.T$24.0B+32%+15%17%27.8×8.8%
Teleflex TFX$6.58B+23%-29%12%16.7×16.5%

How ICU Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ICU Medical against its 20 peers (data as of 18 Nov 2026)
MeasureICUIPeer medianRank in peer set
1-month return+10.8%+3.7%6th highest of 21
6-month return+38.0%+26.1%6th highest of 21
Distance from 52-week high-7.5%-18.0%6th highest of 21
Revenue growth (TTM)-5.8%+8.3%2nd lowest of 21
Operating margin8.1%13.6%6th lowest of 20
Forward P/E19.4×20.5×8th cheapest of 20
Growth the price implies (Req g, 7 yrs)18.9%10.0%3rd most demanding of 18
Growth delivered (Del g)+11.9%+8.2%3rd highest of 18
Hurdle (Req g minus delivered)+7.0 pp+1.5 pp4th most demanding of 18
ROIC minus cost of capital-4.2 pp+2.0 pp6th lowest of 20
EV / EBITDA14.2×12.9×6th most expensive of 14
Net debt / EBITDA2.4×0.5×2nd most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ICU Medical ICUIUnited States$4.46B+38%-6%8%19.4×18.9%+11.9%
GRAIL GRALUnited States$4.59B+67%+17%-332%n/an/an/a
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%

Questions

Who are ICU Medical's main competitors?
Named competitors: Becton Dickinson (BDX), Baxter International (BAX), Fresenius (FRE.DE), Terumo (4543.T), Teleflex (TFX). The cockpit's measured peer set (industry) also includes GRAIL (GRAL), Sotera Health (SHC), Stevanato (STVN), Jiangsu Yuyue Medical Equipment & Supply (002223.SZ), MiniMed (MMED), DiaSorin (DIA.MI).
Is ICU Medical expensive compared with its peers?
On forward p/e it trades at 19.4× against a peer median of 20.5×, 8th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has ICU Medical stock performed?
Over six months to 18 Nov 2026 the shares returned +38.0% against +26.1% for the median peer; over one year +32.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.